Abstract

BackgroundPompe disease is a lysosomal storage disorder caused by the deficiency of acid alpha-glucosidase (EC. 3.2.1.20) due to mutations in human GAA gene. The objective of the present study was to examine clinical and molecular characteristics of infantile-onset Pompe disease (IOPD) in Thailand.MethodsTwelve patients with infantile-onset Pompe disease (IOPD) including 10 Thai and two other Asian ethnicities were enrolled. To examine the molecular characteristics of Pompe patients, GAA gene was analyzed by PCR amplification and direct Sanger-sequencing of 20 exons coding region. The novel mutations were transiently transfected in COS-7 cells for functional verification. The severity of the mutation was rated by study of the GAA enzyme activity detected in transfected cells and culture media, as well as the quantity and quality of the proper sized GAA protein demonstrated by western blot analysis. The GAA three dimensional structures were visualized by PyMol software tool.ResultsAll patients had hypertrophic cardiomyopathy, generalized muscle weakness, and undetectable or < 1% of GAA normal activity. Three patients received enzyme replacement therapy with variable outcome depending on the age of the start of enzyme replacement therapy (ERT). Seventeen pathogenic mutations including four novel variants: c.876C > G (p.Tyr292X), c.1226insG (p.Asp409GlyfsX95), c.1538G > A (p.Asp513Gly), c.1895 T > G (p.Leu632Arg), and a previously reported rare allele of unknown significance: c.781G > A (p.Ala261Thr) were identified. The rating system ranked p.Tyr292X, p. Asp513Gly and p. Leu632Arg as class “B” and p. Ala261Thr as class “D” or “E”. These novel mutations were located in the N-terminal beta-sheet domain and the catalytic domain.ConclusionsThe present study provides useful information on the mutations of GAA gene in the underrepresented population of Asia which are more diverse than previously described and showing the hotspots in exons 14 and 5, accounting for 62% of mutant alleles. Almost all mutations identified are in class A/B. These data can benefit rapid molecular diagnosis of IOPD and severity rating of the mutations can serve as a partial substitute for cross reactive immunological material (CRIM) study.

Highlights

  • Pompe disease is a lysosomal storage disorder caused by the deficiency of acid alpha-glucosidase (EC. 3.2.1.20) due to mutations in human Acid alpha-glucosidase (GAA) gene

  • The disease results from deficiency of alpha glucosidase (GAA) (EC. 3.2.1.20) which catalyzes the hydrolysis of glycogen to glucose, leading to the accumulation of glycogen in lysosomes of skeletal and cardiac muscles, liver and other tissues, with a variety of clinical symptoms [1,2,3]

  • The clinical spectrum is classified into infantile-onset Pompe disease (IOPD) and late-onset Pompe disease (LOPD)

Read more

Summary

Introduction

Pompe disease is a lysosomal storage disorder caused by the deficiency of acid alpha-glucosidase (EC. 3.2.1.20) due to mutations in human GAA gene. Pompe disease is a lysosomal storage disorder caused by the deficiency of acid alpha-glucosidase The objective of the present study was to examine clinical and molecular characteristics of infantile-onset Pompe disease (IOPD) in Thailand. Pompe disease or glycogen storage disease type II (Pompe disease, GSDII, acid maltase deficiency; OMIM; 232,300) is an autosomal recessive lysosomal storage disorder. The disease results from deficiency of alpha glucosidase (GAA) The clinical spectrum is classified into infantile-onset Pompe disease (IOPD) and late-onset Pompe disease (LOPD). IOPD is characterized by onset before 12 months with predominant hypertrophic cardiomyopathy, generalized muscle weakness, hepatomegaly, feeding difficulties, and respiratory compromise. LOPD is characterized by slowly progressive proximal muscle weakness and respiratory insufficiency, either in individuals with onset before 12 months without cardiomyopathy, or in individuals with onset after 12 months. The incidence of Pompe disease has been reported to be about ~ 1 in 40,000 live births around the world [5]

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call